Date | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield | Price to Earnings Ratio (P/E) |
---|
CEO | Mr. Matthew W. Foehr |
IPO Date | Sept. 30, 2021 |
Location | United States |
Headquarters | 5980 Horton Street |
Employees | 106 |
Sector | Health Care |
Industries |
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Past 5 years
USD 48.44
USD 7.66
USD 31.64
USD 5.56
USD 1.93
USD 5.14
USD 27.52
USD 10.01
USD 0.94
USD 1.35
USD 22.74
USD 12.48
USD 1.51
StockViz Staff
January 15, 2025
Any question? Send us an email